Marcella A Kelley1, Stephen D Persell2, Jeffrey A Linder2, Mark W Friedberg3, Daniella Meeker4, Craig R Fox5, Noah J Goldstein5, Tara K Knight6, Dina Zein7, Mark D Sullivan8, Jason N Doctor9. 1. Schaeffer Center for Health Economics and Policy, University of Southern California, Los Angeles, CA, United States of America; School of Pharmacy, University of Southern California, Los Angeles, CA, United States of America. 2. Division of General Internal Medicine and Geriatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, United States of America. 3. Blue Cross & Blue Shield of Massachusetts, Boston, MA, United States of America. 4. Schaeffer Center for Health Economics and Policy, University of Southern California, Los Angeles, CA, United States of America; Keck School of Medicine, University of Southern California, Los Angeles, CA, United States of America. 5. Anderson School of Management, University of California at Los Angeles, Los Angeles, CA, United States of America. 6. Schaeffer Center for Health Economics and Policy, University of Southern California, Los Angeles, CA, United States of America; Sol Price School of Public Policy, University of Southern California, Los Angeles, CA, United States of America. 7. Schaeffer Center for Health Economics and Policy, University of Southern California, Los Angeles, CA, United States of America. 8. School of Medicine, University of Washington, Seattle, WA, United States of America. 9. Schaeffer Center for Health Economics and Policy, University of Southern California, Los Angeles, CA, United States of America; School of Pharmacy, University of Southern California, Los Angeles, CA, United States of America; Sol Price School of Public Policy, University of Southern California, Los Angeles, CA, United States of America. Electronic address: jdoctor@usc.edu.
Abstract
BACKGROUND: High levels of opioid prescribing in the United States has resulted in an alarming trend in opioid-related harms. The objective of Trial 2 of the Application of Economics & Social psychology to improve Opioid Prescribing Safety (AESOPS-2) is to dampen the intensity and frequency of opioid prescribing in accordance with the Centers for Disease Control and Prevention recommendation to "go low and slow". We aim to accomplish this by notifying clinicians of harmful patient outcomes, which we expect to increase the mental availability of risks associated with opioid use. METHODS: The trial is multi-site. Random assignment determines if prescribers to persons who suffer an opioid overdose (fatal or nonfatal) learn of this event (intervention) or practice usual care (control). Clinicians in the intervention group receive a letter notifying them of their patient's overdose. The primary outcome is the change in clinician weekly milligram morphine equivalent (MME) prescribed in a 6-month period before and after receiving the letter. Additional outcomes are the change in the proportion of patients prescribed at least 50 daily MME and in the proportion of patients referred to medication assisted treatment. Group differences in these outcomes will be compared using an intent-to-treat difference-in-differences framework with a mixed-effects regression model to estimate clinician MME. DISCUSSION: The AESOPS-2 trial will provide new knowledge about whether increasing prescribers' awareness of patients' opioid-related overdoses leads to a reduction in opioid prescribing. Additionally, this trial may better inform how to reduce opioid use disorder and opioid overdoses by lowering population exposure to these drugs. TRIAL REGISTRATION: ClinicalTrials.gov: NCT04758637.
BACKGROUND: High levels of opioid prescribing in the United States has resulted in an alarming trend in opioid-related harms. The objective of Trial 2 of the Application of Economics & Social psychology to improve Opioid Prescribing Safety (AESOPS-2) is to dampen the intensity and frequency of opioid prescribing in accordance with the Centers for Disease Control and Prevention recommendation to "go low and slow". We aim to accomplish this by notifying clinicians of harmful patient outcomes, which we expect to increase the mental availability of risks associated with opioid use. METHODS: The trial is multi-site. Random assignment determines if prescribers to persons who suffer an opioid overdose (fatal or nonfatal) learn of this event (intervention) or practice usual care (control). Clinicians in the intervention group receive a letter notifying them of their patient's overdose. The primary outcome is the change in clinician weekly milligram morphine equivalent (MME) prescribed in a 6-month period before and after receiving the letter. Additional outcomes are the change in the proportion of patients prescribed at least 50 daily MME and in the proportion of patients referred to medication assisted treatment. Group differences in these outcomes will be compared using an intent-to-treat difference-in-differences framework with a mixed-effects regression model to estimate clinician MME. DISCUSSION: The AESOPS-2 trial will provide new knowledge about whether increasing prescribers' awareness of patients' opioid-related overdoses leads to a reduction in opioid prescribing. Additionally, this trial may better inform how to reduce opioid use disorder and opioid overdoses by lowering population exposure to these drugs. TRIAL REGISTRATION: ClinicalTrials.gov: NCT04758637.
Authors: Jason N Doctor; Andy Nguyen; Roneet Lev; Jonathan Lucas; Tara Knight; Henu Zhao; Michael Menchine Journal: Science Date: 2018-08-10 Impact factor: 47.728
Authors: Kate M Dunn; Kathleen W Saunders; Carolyn M Rutter; Caleb J Banta-Green; Joseph O Merrill; Mark D Sullivan; Constance M Weisner; Michael J Silverberg; Cynthia I Campbell; Bruce M Psaty; Michael Von Korff Journal: Ann Intern Med Date: 2010-01-19 Impact factor: 25.391
Authors: Gery P Guy; Kun Zhang; Michele K Bohm; Jan Losby; Brian Lewis; Randall Young; Louise B Murphy; Deborah Dowell Journal: MMWR Morb Mortal Wkly Rep Date: 2017-07-07 Impact factor: 17.586
Authors: Wändi Bruine de Bruin; Carmen E Lefevre; Andrea L Taylor; Suraje Dessai; Baruch Fischhoff; Sari Kovats Journal: J Exp Psychol Appl Date: 2016-06-06
Authors: Jan Klimas; Lauren Gorfinkel; Nadia Fairbairn; Laura Amato; Keith Ahamad; Seonaid Nolan; David L Simel; Evan Wood Journal: JAMA Netw Open Date: 2019-05-03